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Abstract 
Background: Oral potentially malignant disorders harbour unpredictable risk for 
squamous cell carcinoma development. Current management requires tissue biopsy 
for histopathology characterisation, dysplasia grading and targeted intervention to 
‘high risk’ lesions, although evidence-based guidelines are limited and diagnoses 
subjective. This study investigated the use of adjunctive oral brush biopsy 
techniques during the management of potentially malignant disorders in a UK 
hospital population.  
Methods: Retrospective review of a 310 PMD patient cohort presenting to 
Maxillofacial Surgery in Newcastle upon Tyne with new, single-site lesions between 
December 2009 and May 2014. Patients underwent Orcellex® brush biopsy and 
liquid-based cytology examination in addition to conventional biopsy techniques, with 
management proceeding along established care pathways. Patient demographics, 
cytology data, most significant histopathology diagnoses and clinical outcome were 
all documented at the study census date (31.12.15).  
Results: 170 male & 140 female patients (age range 18-91yrs), exhibiting primarily 
leukoplakia (86.5%) at floor of mouth and ventro-lateral tongue sites (44.9%), were 
identified. Management comprised: observation (49.7%), laser surgery (44.9%), anti-
fungal treatment (3.5%), and Head & Neck clinic referral following cancer diagnosis 
(1.9%). Clinical outcomes were: disease free (51.3%), persistent PMD (42.3%) and 
malignant transformation (6.4%). Histology and cytology diagnoses strongly 
correlated (r=0.305). Treatment modality, lesion site, histology and cytology 
diagnoses were the best predictors of clinical outcome.  
Conclusions: Orcellex® brush cytology provides reliable diagnoses consistent with 
conventional histopathology and offers less invasive, adjunctive assessment 
appropriate for long-term monitoring of patients in specialist clinics.  
 
 
 
 
3 
 
 
Introduction 
Oral squamous cell carcinoma (SCC) may be preceded by potentially malignant 
disorders (PMD), distinct mucosal lesions such as leukoplakia, erythroplakia, or 
erythroleukoplakia, or more widespread disorders such as proliferative verrucous 
leukoplakia (PVL)1,2. Characteristic of PMD is the variable histopathological 
presence of epithelial disorganisation and dysmaturation which is characterised 
microscopically as dysplasia1,2. Whilst the natural history of PMD remains poorly 
understood, recent systematic reviews have estimated a 12% cancer risk over a 
mean transformation time of 4.3 years3. Early diagnosis and intervention during the 
progression of worsening dysplasia towards SCC thus has potential to improve 
prognosis and reduce morbidity1. 
Despite the ability to identify PMD in patients, assessment techniques are highly 
subjective and clinicians are unable to predict lesion behaviour or quantify individual 
risk for malignant transformation1. Contemporary PMD management is based upon 
incision biopsy for histological confirmation followed by lesion excision, often via CO2 
laser, for definitive diagnosis and treatment of ‘high risk’ lesions4,5,6. Tissue biopsy 
and histopathological grading of dysplasia, although remaining the gold standard for 
PMD diagnosis, has been criticised as invasive, expensive, subjective and ultimately 
unrepresentative, especially for large, multi-focal lesions1,2.   
Non-invasive adjunctive diagnostic tools were proposed to improve detection of early 
signs of cancer change in oral mucosa. These include vital staining, optical imaging 
and brush biopsy cytology although reports of effectiveness are anecdotal, there is 
criticism they rarely reveal features not demonstrable by conventional techniques 
and their role in contemporaneous clinical practice remains unclear7,8. 
Cytodiagnosis is the technique whereby individual cells are loosened from their 
tissue of origin and transferred to a cytology slide for microscopic examination. 
Whilst effective sampling of exfoliated oral epithelial cells for analysis has proved 
unreliable, newer collection devices including a range of ‘cytobrushes’ have been 
developed to facilitate full-thickness sampling of stratified epithelium9. The Orcellex® 
brush (Rovers Medical Devices BV., the Netherlands) has a specially designed head 
comprising 5 segments of high-density fibres designed for optimal cell collection, 
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storage and predictable release of cells from multiple layers of oral epithelium 
(Figure 1A). In clinical practice, the brush head is firmly placed against the mucosa 
and rotated 10 times (Figure 1B), then detached and transferred in BD SurePathTM 
ethanol-based preservative fluid for laboratory transfer. The use of liquid-based 
cytology (LBC), rather than conventional glass slide smears, improves cell 
distribution and produces thin layer preparations (Figure 1C). Whilst preliminary trials 
on the use of the Orcellex® brush have been reported9-11, the accuracy of brush 
cytology requires formal assessment as an objective tool during long term PMD 
management. 
The aim of this study was thus to review the efficacy of adjunctive oral brush biopsy 
techniques during the diagnosis and interventional management of PMD and to 
assess the accuracy and potential predictive value of the technique in direct 
comparison to conventional clinico-pathological data.  
 
Materials and Methods 
Patients and treatment  
Caldicott Approval from Newcastle University / Newcastle upon Tyne Hospitals NHS 
Foundation Trust facilitated anonymized, retrospective data collection from medical 
records, operating logs, cytology and pathology reports from PMD patients treated 
by the senior author (PJT) and attending Newcastle Dental and Royal Victoria 
Infirmary hospitals between December 2009 and May 2014. Inclusion criteria 
required new, untreated single-site PMD where Orcellex® brush biopsy and liquid-
based cytology (LBC) were performed in addition to conventional biopsy procedures. 
Patient management proceeded along established PMD care pathways4. 
Demographic and clinico-pathological data obtained for each patient comprised: age, 
sex, clinical appearance and site of oral lesion, cytology and histopathology 
diagnoses from original reports, and clinical outcome documented on the study 
census date (31 December 2015). Patients with previous or multi-focal PMD, and 
those with a history of OSCC or head and neck radiotherapy were excluded.    
Cytology 
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Patients underwent Orcellex® brush biopsy as illustrated in Figure 1. Cytology 
specimens were processed and stained using the BD Prep StainTM automated 
process in which, following density gradient centrifugation to enrich the cellular 
sample and remove non-diagnostic debris, discretely stained, thin-layer slide 
preparations were produced. Each specimen was stained with Papanicolau and 
Periodic Acid Schiff. Specimen reporting was carried out by experienced cytologists 
applying the Bethesda guidelines for liquid-based squamous cellularity12; discussion 
and consensus grading was carried out when required. Cells were described as 
normal (including normal and hyperkeratosis categories), exhibiting mild, moderate 
or severe dyskaryosis, or suggestive of SCC; inflammatory cells and candida were 
noted as appropriate. 
Histopathology 
Incision biopsies were performed under the direction of PJT and excision specimens 
obtained following interventional laser treatment. Laser surgery was performed by 
PJT, or by colleagues working under direct supervision, according to previously 
detailed protocols within 6-12 weeks following lesion presentation to avoid disease 
progression4-6. Formalin-fixed biopsy specimens underwent standardized 
histopathology examination by experienced oral pathologists working to agreed 
diagnostic criteria and using the World Health Organisation (WHO) classification to 
grade tissue as normal (including hyperkeratosis), mild, moderate and severe 
dysplasia, carcinoma-in-situ (CiS) or SCC. The most severe histopathological 
diagnosis obtained from original incision or excision biopsy reports was recorded for 
each patient. In addition, the presence of lichenoid inflammation (LI), and diagnoses 
of PVL and candida infection were recorded.   
Statistical Analysis 
Descriptive statistics were used to detail patient demography, clinical features, 
cytological and histopathological diagnoses, treatment interventions and follow-up 
data. Clinical outcomes were stratified into disease-free or further disease (persistent 
or SCC development) categories and both univariate and multivariate logistic 
regression analyses were performed. Brush cytology and most significant 
histopathology diagnoses were treated as categorical variables, and Cramer’s V 
assessment of correlation undertaken. Sensitivity scores, whereby cytology and 
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histopathology diagnoses were coded as binary variables, were calculated. In 
relation to SCC, calculations of sensitivity (proportion of correctly identified positive 
results), specificity (proportion of correctly identified negative results), and positive 
and negative predictive values for the Orcellex® brush were determined. Statistical 
analyses were performed using SPSS, version 19.0 (Statistical Package for the 
Social Sciences, Chicago, IL, USA). 
Results 
Table 1 summarises study results: 310 patients met the search criteria, 140 men 
(mean age 57.8 years) and 170 women (mean age 59.8 years). Of the 310 lesions 
assessed, 268 presented as leukoplakias (86.5%), with erythroleukoplakia (27) and 
erythroplakia (15) less common. Floor of mouth and ventro-lateral tongue together 
comprised the most commonly affected site in 139 cases (44.9%).  
All brush cytology samples were of diagnostic quality with 164 specimens reported 
as ‘normal’, 137 displaying variable severity of dyskaryosis and 9 suggestive of SCC. 
Histopathological diagnoses, based upon the most significant abnormality observed, 
reported 165 ‘normal’ specimens with 131 exhibiting dysplasia and 14 CiS or 
invasive SCC. Review of  diagnostic categories listed in Table 1 and the cytology 
versus histopathology cross-tabulation presented in Table 2 reveal a very similar 
distribution; correlation coefficient r=0.305 (Cramer’s V association) confirmed a 
moderately strong relationship between results. Whilst reasonable sensitivity and 
positive predictive values for brush cytology to detect SCC were seen, specificity and 
negative predictive values were much higher; Table 3. 
Candida hyphae were identifiable in both cytology and histology specimens (10% 
and 4.8% respectively), but features of LI (28.7%) and PVL (11.3%) were only 
characterised by histopathological examination. 
154 patients (49.7%) were managed by clinical observation alone (principally 
‘normal’ or ‘mild dyskaryosis/dysplasia’ cases), whilst 139 (44.9%) underwent laser 
surgery (usually excision biopsy); medical (anti-fungal) treatment or referral to Head 
& Neck oncology clinics was the principal treatment modality in 17 cases (5.4%). 
Patient follow-up ranged from 17 to 72 months (mean 57.9 months). Clinical 
outcome data showed 159 patients (51.3%) to be free of clinically observable 
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mucosal disease at study census date, whilst 151 (48.7%) exhibited persistent 
disease or had undergone SCC transformation. Review of clinico-pathological 
variables potentially influencing clinical outcome (listed in Table 4 and presented 
graphically in Figure 2) suggested that treatment modality (in particular the absence 
of laser treatment), lesion site, histopathology and cytology diagnoses were the best 
predictors of developing further disease; histopathology exerted an 11% influence, 
whilst cytology 7% suggesting histopathology to be a 1.6 times better predictor than 
cytology. In contrast, patient age, sex, lesion appearance, and the presence of 
candida, LI or PVL were all less predictive of outcome.   
Discussion 
This paper analysed a cohort of 310 treated PMD patients examined by Orcellex® 
brush biopsy in addition to conventional histopathology, and confirmed diagnostic 
reliability together with a potential predictive role. The majority of PMD lesions were 
leukoplakias on floor of mouth and ventro-lateral tongue sites, with nearly half 
exhibiting dysplasia or SCC and undergoing interventional laser treatment, 
consistent with our previously reported patient cohorts4-6. In contrast, recent cytology 
studies have involved less specific mucosal disease, smaller patient numbers and no 
clinical outcome data13-16. Whilst we previously compared cytology with incision 
biopsy diagnoses for 224 patients in an Orcellex® brush trial, many of those lesions 
were not dysplastic, no excision biopsies were studied and no treatment or long term 
follow-up data were available11.  
The Orcellex® brush appears a useful adjunctive diagnostic technique: readily 
available in clinic, easy to use, minimally invasive and efficient in cell collection11,13. 
From a clinician perspective, the brush has an optimal design facilitating application 
to oral sites. Patients report a preference for brush in contrast to conventional 
techniques requiring local anaesthetic, scalpel or punch instrumentation and 
suturing11.  The brush provides trans-epithelial sampling of basal, para-basal and 
superficial cell layers important for cytology grading, especially relevant in thickened 
keratin layers characteristic of leukoplakia, the commonest PMD.  
A further advantage of LBC is the option to perform additional analyses such as 
immunocytochemistry, HPV testing, DNA-ploidy, or the measurement of biomarkers 
in cells left over in collection fluid after diagnostic smear preparation9,17; we have 
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previously demonstrated high Ki-67 labelling in PMD lesions with aggressive 
disease, so there may be an enhanced prognostic role for future labelling studies 
(Figure 1D)18. 
Whilst significant correlation was seen between cytology and histopathology 
diagnoses (134 study samples matched precisely; Table 2), direct comparison may 
not always be feasible due to variations in cytology terminology and lack of available 
tissue structure, which is essential for histopathological characterisation of LI and 
PVL and pertinent for patients developing further or persistent PMD6. 
Prediction of clinical outcome remains elusive in clinical practice, especially for 
individual patient management4-6. In this study the choice of treatment modality, in 
particular not administering laser surgery, was seen on multivariate analysis to be a 
predictor of further disease; probably unsurprising due to laser’s efficacy in PMD 
excision6. Whilst histopathology diagnoses were better predictors of outcome than 
cytology, brush biopsy appeared more accurate than traditional clinico-pathological 
data such as patient age, sex, clinical lesion appearance or additional features such 
as candidal infection, LI and PVL. 
Malignant transformation rates for PMD vary worldwide, with quoted ranges varying 
between 0.1% and 40% and an overall mean of 12%, although we have highlighted 
that up to 12% of PMDs may already harbour invasive SCC on initial presentation6. 
LBC, in the absence of histological confirmation, can only raise suspicion that 
abnormal cells have arisen in an invasive SCC. It is notable, however, that we found 
the number of cytology and histopathology SCC diagnoses similar at 9 and 14 cases 
respectively (the latter included 4 CiS cases; Table 1). 
Whilst the sensitivity and positive predictive values for brush detected SCC were 
reasonable (60% and 67% respectively), specificity and negative predictive values 
showed high credibility (99%). Orcellex® brush biopsy therefore, whilst not a 
substitute for conventional biopsy and histological examination, offers additional 
‘screening’ opportunities for abnormal cell identification especially for sampling of 
large, widespread or multi-focal lesions during long-term monitoring and active 
surveillance of patients post-PMD treatment6. 
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This clinico-pathological review took place within a single-centre, specialist PMD 
service and was not a prospective, randomized controlled trial. Nonetheless, the 
study supports Orcellex® brush biopsy and LBC as practical, effective and reliable 
adjunctive diagnostic techniques during management of a 310 PMD patient cohort 
followed for up to 6 years in a hospital setting. 
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Table 1: Patient Demographic, Clinico-Pathological and Outcome Data for PMD 
Patients (Number = 310). 
Patient Sex                                                                        No.  (%) 
Male 170 (54.8%) 
Female 140 (45.2%) 
Patient Age Mean Years (SD) 
Male 57.8 (12.38) 
Female 59.8 (12.56) 
Lesion                                                                          No.  (%) 
Leukoplakia     268 (86.5%)  
Erythroleukoplakia                                                                  27   (8.7%) 
Erythroplakia 15 (4.8%) 
Site                                                                        No.  (%) 
Floor Of Mouth                                                                   62  (20%) 
Lateral Tongue                                                                   60 (19.4%) 
Buccal Mucosa                                                                   55 (17.7%) 
Palate                                                                   38 (12.3%) 
Alveolus                                                                   24   (7.7%) 
Gingiva                                                                   18   (5.8%) 
Ventral Tongue                                                                   17   (5.5%) 
Dorsum of Tongue                                                                   13   (4.2%) 
Labial Mucosa                                                                   11   (3.5%) 
Fauces / Retromolar Region                                                                     7   (2.3%) 
Labial Commissure                                                                     5  (1.6%) 
Brush Cytology Diagnosis No. (%) 
Normal 164 (52.9%) 
Atypia / Mild Dyskaryosis 79 (25.5%) 
Moderate Dyskaryosis 26 (8.4%) 
Severe Dyskaryosis 32 (10.3%) 
? SCC 9 (2.9%) 
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Histopathology Diagnosis (Most Significant) No. (%) 
Normal 165 (53.2%) 
Mild Dysplasia 74 (23.9%) 
Moderate Dysplasia 34 (11%) 
Severe Dysplasia  23 (7.4%) 
Carcinoma in Situ / SCC 14 (4.5%) 
Lichenoid Inflammation No. (%) 
Yes 89 (28.7%) 
No 221 (71.3%) 
PVL No. (%) 
Yes 34 (11.3%) 
No 276 (91.7%) 
Candida (Cytology Diagnosis) No. (%) 
Yes 31 (10%) 
No 279 (90%) 
Candida (Histopathology Diagnosis) No. (%) 
Yes 15 (4.8%) 
No 295 (95.2%) 
Treatment Intervention  No. (%) 
Observation 154 (49.7%) 
Laser Treatment 139 (44.9%) 
Medical Treatment 11 (3.5%) 
Referral to Head & Neck MDT 6 (1.9%) 
Clinical Outcome   
Disease Free                                                                 159 (51.3%) 
Persistent Disease                                                                 131 (42.3%) 
Malignant Transformation                                                                   20   (6.4%)  
 
 
 
Table 2: Cross-tabulation of the Number of Cases and Sensitivity Scores 
(parentheses) for Cytology vs. Histopathology Diagnoses. 
 
 
 HISTOPATHOLOGY DIAGNOSES Total 
Normal Mild Dysp Mod Dysp Severe Dysp CiS/SCC 
CYTOLOGY 
DIAGNOSES 
 
Normal 
 
100 (0.61) 
 
42 (0.57) 
 
13 (0.38) 
 
7 (0.3) 
 
2 (0.14) 
 
164 
Mild Dysk 46 (0.28) 17 (0.23) 10 (0.29) 4 (0.17) 2 (0.14) 79 
14 
 
Moderate Dysk 7 (0.04) 6 (0.08) 5 (0.15) 5 (0.22) 3 (0.21) 26 
Severe Dysk 
?SCC 
 
11 (0.07) 
1 (0.01) 
8 (0.11) 
1 (0.01) 
6 (0.18) 
0 (0) 
6 (0.26) 
1 (0.04) 
1 (0.07) 
6 (0.43) 
32 
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  Total 165 74 34 23 14 310 
 
For computation of sensitivity scores, each cytology and histopathology diagnoses were coded as binary 
variables (not present/present). 
Abbreviations: Mod = Moderate; Dysk = Dyskaryosis; Dysp = Dysplasia; CiS  = Carcinoma in Situ; SCC = 
Squamous Cell Carcinoma 
 
Table 3: Sensitivity, Specificity, Positive and Negative Predictive Values for 
Orcellex® Brush Cytology detecting Squamous Cell Carcinoma (SCC), assuming 
Histopathology as ‘gold standard’. 
 
Test % 
Sensitivity  
 
60 
Specificity 
 
99 
Positive Predictive Value 
 
67 
Negative Predictive Value 
 
99 
 
 
Table 4: Analysis of clinico-pathological factors influencing further disease status. 
 
Clinico-Pathological Factor Univariate Analysis 
 (P value) 
Multivariate Model 
(P value) 
Age ------ Linear: 0.67; Non-Linear 0.79 
Sex 0.82 0.52 
Site <0.001 0.14 
Histology <0.001 0.17 
Cytology 0.15 0.36 
Clinical Appearance 0.75 0.98 
PVL 0.23 0.78 
Lichenoid Inflammation 0.28 0.51 
Candida 0.17 0.26 
15 
 
Treatment Modality <0.001 <0.001 
 
 
 
 
 
 
 
 
Figure 1: (A) Orcellex® brush head in close-up showing high-density fibres for optimal cell 
collection (B) brush in use clinically for floor of mouth sampling, (C) Papanicolaou stained 
thin-layer LBC preparation under microscopy (x40) and (D) high Ki67 labelling seen in 
dyskaryosis (x100). 
 
 
Figure 2: Contribution of independent variables in predicting outcome from the multiple 
logistic regression model. 
 
